Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC)
comprises a distinct molecular entity with a reported global prevalence of 5–7%. The …

The advent of stratified medicine and tailored therapies has caused non-small cell lung
cancer (NSCLC) to become a subject of keen interest, with an emphasis on comprehensive …

In the quest to improve the diagnosis and treatment of non-small-cell lung carcinoma
(NSCLC), particularly in cases involving anaplastic lymphoma kinase (ALK) gene …

Background: Accurate molecular testing in non-small-cell lung cancer (NSCLC) is of
paramount importance for treatment, prediction, and prognostication. Objectives: We aimed …

Targeted drugs for driver mutations in lung cancers have laid the foundation for precision
oncology medicine. The present outcomes in patients with driver-mutated lung cancer were …

A 57‑year‑old female patient with no comorbidities or family history of cancer presented with
a 3‑month history of vaginal mass and spotting. Past obstetric history revealed that she was …

I read with interest yet another fascinating report that reiterates the promise of precision
medicine, as observed in a 42‑year‑old patient with ROS1 rearranged Stage IV lung …

Rearranged during transfection (RET) alteration promotes oncogenesis in a few cancers.
RET mutation positivity is seen in approximately 70% of medullary thyroid cancers, around …

Lung cancer is one of the most dreaded causes of cancer-related mortality across the globe,
including in India.[1, 2] Over the last decade, there has been a paradigm shift in the …

Batra et al., in their case series, have reported the utility of RET fusions/rearrangements as a
potential biomarker for lung carcinomas.[1] In this study, the next‑generation sequencing …